<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">34542699</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2102</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Der Radiologe</Title><ISOAbbreviation>Radiologe</ISOAbbreviation></Journal><ArticleTitle>[COVID-19: epidemiology and mutations : An update].</ArticleTitle><Pagination><MedlinePgn>880-887</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00117-021-00909-0</ELocationID><Abstract><AbstractText>Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can enhance the spread and the infectiousness and decrease the protective effect of antibodies present after infection, vaccination or antibody treatment. The alpha variant (B.1.1.7), first seen in Kent/United Kingdom, has increased the R‑value and therefore the infectiousness by 75%; however, the effectiveness of the vaccines against SARS-CoV‑2 available in Germany seems to be only slightly impaired by these mutations. In the case of the beta variant (B.1.351), first described in South Africa, the neutralization ability of antibodies towards SARS-CoV‑2 is decreased. The monoclonal antibodies bamlanivimab and etesivimab, which are used therapeutically, are ineffective. The AstraZeneca vaccine offers almost no protection against mild or moderate disease caused by the beta variant. The gamma variant (P.1 or B.1.1.28.1), which was first found in Brazil, is probably 1.7-2.6 times more transmissible than previous virus strains circulating in Brazil. In addition to the infectiousness, the mortality risk of the gamma variant also seems to be increased between 1.2 and 1.9-fold in adults and between 5 and 8-fold in young persons. The delta variant (B.1.617), first described in India, is now dominant in most countries. It is 50% more infectious than the alpha variant, and the protective effect of vaccinations against symptomatic disease can be decreased (Biontech: delta variant 88%, alpha variant 93.7%; AstraZeneca: delta variant 67%, alpha variant 74.5%). Furthermore, the course of the disease with the delta variant is often more severe than with the wild type. Disease courses with the delta variant are less severe in vaccinated than in nonvaccinated persons, and fatal outcomes are substantially rarer. A high vaccination rate is essential in order to approach herd immunity and to bring the pandemic under control. Even where the protective effect towards mild or moderate disease is decreased, as a rule, vaccination still offers excellent protection against life-threatening and fatal disease courses.</AbstractText><CopyrightInformation>© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hemmer</LastName><ForeName>Christoph J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Abteilung für Tropenmedizin und Infektionskrankheiten, Universitätsmedizin Rostock, Ernst-Heydemann-Straße 5, 18057, Rostock, Deutschland. Christoph.Hemmer@uni-rostock.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Löbermann</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Abteilung für Tropenmedizin und Infektionskrankheiten, Universitätsmedizin Rostock, Ernst-Heydemann-Straße 5, 18057, Rostock, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisinger</LastName><ForeName>E C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Abteilung für Tropenmedizin und Infektionskrankheiten, Universitätsmedizin Rostock, Ernst-Heydemann-Straße 5, 18057, Rostock, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>COVID-19: Epidemiologie und Mutationen : Ein Update.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Radiologe</MedlineTA><NlmUniqueID>0401257</NlmUniqueID><ISSNLinking>0033-832X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText Label="ZUSAMMENFASSUNG" NlmCategory="UNASSIGNED">Mutationen von SARS-CoV‑2 können die Ausbreitungsfähigkeit und Infektiosität erhöhen sowie die Schutzwirkung von Antikörpern vermindern, die nach einer Infektion, einer Impfung oder einer Antikörpertherapie vorhanden sind. Die Alpha-Variante (B.1.1.7), die zuerst in Kent/Großbritannien beobachtet wurde, hat zu einer Erhöhung des R‑Werts und damit der Infektiosität um 75 % geführt. Die Wirksamkeit der in Deutschland verfügbaren Impfungen gegen SARS-CoV‑2 scheint durch diese Mutationen jedoch nur geringfügig beeinträchtigt zu sein. Bei der Beta-Variante (B.1.351), die zuerst in Südafrika beschrieben wurde, ist die Fähigkeit von Antikörpern, SARS-CoV‑2 zu neutralisieren, vermindert. Die therapeutisch verwendeten monoklonalen Antikörper Bamlanivimab und Etesivimab sind unwirksam. Der Impfstoff von AstraZeneca hat gegenüber leichten und mittelschweren Erkrankungen durch die Beta-Variante fast keine Schutzwirkung. Die Gamma-Variante (P.1 oder B.1.1.28.1), die zuerst in Brasilien gefunden wurde, ist wahrscheinlich um den Faktor 1,7 bis 2,6 stärker übertragbar als zuvor in Brasilien zirkulierende Virusstämme. Neben der Infektiosität scheint auch das Sterberisiko bei der Gamma-Variante um den Faktor 1,2 bis 1,9 bei Erwachsenen und bei jüngeren Patienten um den Faktor 5 bis 8 erhöht zu sein. Die Delta-Variante (B.1.617), die zuerst in Indien beschrieben wurde, ist inzwischen in den meisten Ländern dominierend. Ihre Infektiosität ist gegenüber der zuvor dominierenden Alpha-Variante um etwa 50 % erhöht, die Schutzwirkung der verfügbaren Impfungen vor symptomatischen Erkrankungen kann vermindert sein (BioNTech: Delta-Variante 88 %, Alpha-Variante 93,7 %; AstraZeneca: Delta-Variante 67 %, Alpha-Variante 74,5 %). Ferner ist der Krankheitsverlauf bei der Delta-Variante oft schwerer als beim Wildtyp. Erkrankungen durch die Delta-Variante verlaufen bei Geimpften leichter als bei Ungeimpften, und tödliche Verläufe sind wesentlich seltener. Eine hohe Impfquote ist unerlässlich, um einer Herdenimmunität möglichst nahezukommen und die Pandemie unter Kontrolle zu bringen. Selbst bei verminderter Schutzwirkung gegenüber leichten und mittelschweren Erkrankungen bieten Impfungen in der Regel einen ausgezeichneten Schutz gegenüber lebensbedrohlichen und tödlichen Krankheitsverläufen.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease severity</Keyword><Keyword MajorTopicYN="N">Infectiousness</Keyword><Keyword MajorTopicYN="N">SARS-CoV‑2</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword><Keyword MajorTopicYN="N">Virus variants</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>20</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34542699</ArticleId><ArticleId IdType="doi">10.1007/s00117-021-00909-0</ArticleId><ArticleId IdType="pii">10.1007/s00117-021-00909-0</ArticleId><ArticleId IdType="pmc">PMC8450702</ArticleId></ArticleIdList><ReferenceList><Title>Literatur</Title><Reference><Citation>https://www.worldometers.info/coronavirus/ . Zugegriffen: 2. Aug. 2021</Citation></Reference><Reference><Citation>Kirby T (2021) New variant of SARS-CoV‑2 in UK causes surge of COVID-19. Lancet Respir Dis. https://doi.org/10.1016/S2213-2600(21)00005-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00005-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung K, Shum MHH, Leung GM, Lam TTY, Wu JT (2021) Early transmissibility assessment of the N501Y mutant strains of SARS-CoV‑2 in the United Kingdom, October to November 2020. Euro Surveill. https://doi.org/10.2807/1560-917.ES.2020.26.1.2002106</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-917.ES.2020.26.1.2002106</ArticleId><ArticleId IdType="pubmed">33413740</ArticleId><ArticleId IdType="pmcid">7791602</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies NG, Jarvis CI, CMMID COVID-19 Working Group et al (2021) Increased mortality in community-tested cases of SARS-CoV‑2 lineage B.1.1.7. Nature 593:270–274</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03426-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorne LG, Bouhaddou M, Reuschl AK et al (2021) Evolution of enhanced innate immune evasion by the SARS-CoV‑2 B.1.1.7 U.K. variant. BioRxiv. https://doi.org/10.1101/2021.06.06.446826 (Preprint)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.06.446826</ArticleId></ArticleIdList></Reference><Reference><Citation>RKI Bericht zu Virusvarianten von SARS-CoV‑2 in Deutschland. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/DESH/Bericht_VOC_2021-04-28.pdf?__blob=publicationFile (Erstellt: 28. Apr. 2021). Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Graham MS, Sudre CH, May A et al (2021) Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV‑2 variant B.1.1.7: an ecological study. Lancet 6:E335–E345. https://doi.org/10.1016/S2468-2667(21)00055-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(21)00055-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Nair MS, Liu L et al (2021) Antibody resistance of SARS-CoV‑2 variants B.1.351 and B.1.1.7. Nature 593:130–135. https://doi.org/10.1038/s41586-021-03398-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03398-2</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId><ArticleId IdType="pmcid">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X, Tang H, McDanal C et al (2021) SARS-CoV‑2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29:529–539.e3. https://doi.org/10.1016/j.chom.2021.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.002</ArticleId><ArticleId IdType="pubmed">33705729</ArticleId><ArticleId IdType="pmcid">7934674</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM et al (2021) Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV‑2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397:P1819–P1829. https://doi.org/10.1016/S0140-6736(21)00947-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England (2021) Research and analysis. Variants: distribution of cases data. https://www.gov.uk/government/publications/covid-19-variants-genomically-confirmed-case-numbers/variants-distribution-of-cases-data (Erstellt: 27. Mai 2021). Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Emary et al (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV‑2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet 397(10282):P1351–P1362. https://doi.org/10.1016/S0140-6736(21)00628-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00628-0</ArticleId></ArticleIdList></Reference><Reference><Citation>https://cov-lineages.org/global_report_B.1.351.html . Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Karim SSA, de Oliveira T (2021) New SARS-CoV‑2 Variants—Clinical, Public Health, and Vaccine Implications. N Engl J Med 384:1866–1868. https://doi.org/10.1056/NEJMc2100362</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2100362</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson CAB, Russell TW, Davies N et al (2021) Estimates of severity and transmissibility of novel SARS-CoV‑2 variant 501Y.V2 in South Africa. CMMID Repository. https://cmmid.github.io/topics/covid19/sa-novel-variant.html (under review). Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Dolgin E Coronavirus Variant threatens global recovery. Nature. News Feature. https://www.nature.com/articles/d44148-021-00021-4 . Zugegriffen: 14. Apr. 2021</Citation></Reference><Reference><Citation>Brum E, Saha S, Sania A et al (2021) Surging COVID-19 in Bangladesh driven by B.1.351 variant. medRxiv. https://doi.org/10.1101/2021.04.27.21255706</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.27.21255706</ArticleId></ArticleIdList></Reference><Reference><Citation>CNN https://edition.cnn.com/2020/06/09/africa/tanzania-president-covid-claims/index.html (Erstellt: 9. Juni 2020). Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>https://edition.cnn.com/2021/02/11/africa/tanzania-covid-cases-surge-intl/index.html . Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Yadav PD (2021) Imported SARS-CoV‑2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India. Travel Med Infect Dis. https://doi.org/10.1016/j.tmaid.2021.102023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021.102023</ArticleId><ArticleId IdType="pubmed">33727176</ArticleId><ArticleId IdType="pmcid">7955805</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta RK (2021) Will SARS-CoV‑2 variants of concern affect the promise of vaccines? Nat Rev Immunol 21:340–341</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00556-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X, Yan R, Zhang J et al (2020) A neutralizing human antibody binds to the N‑terminal domain of the Spike protein of SARS-CoV‑2. Science 369:650–655. https://doi.org/10.1126/science.abc6952</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6952</ArticleId><ArticleId IdType="pubmed">32571838</ArticleId><ArticleId IdType="pmcid">7319273</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D et al (2021) Sensitivity of infectious SARS-CoV‑2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 27:917–924</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01318-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W, Mudara C, Ozougwu L et al (2021) Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. Lancet. https://doi.org/10.1016/S2214-109X(21)00289-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(21)00289-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Staub T, Arend V, de la Vega ECL et al (2021) Case series of four re-infections with a SARS-CoV‑2 B.1.351 variant, Luxembourg, February 2021. Euro Surveill. https://doi.org/10.2807/1560-7917.ES.2021.26.18.2100423</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.18.2100423</ArticleId><ArticleId IdType="pubmed">33960291</ArticleId><ArticleId IdType="pmcid">8103728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer CK, Ayres F, Hermanus T et al (2021) SARS-CoV‑2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med 27:622–625</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01285-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahdi SA, Baillie V, Cutland CL et al (2021) Efficacy of the ChAdOx1 nCoV-19 COVID-19 Vaccine against the B.1.351 Variant. N Eng J Med 384:1885–1898. https://doi.org/10.1056/NEJMoa2102214</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102214</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Liu J, Xia H et al (2021) Neutralizing activity of BNT162b2-elicited serum. N Eng J Med 384:1466–1468. https://doi.org/10.1056/NEJMc2102017</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2102017</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad LJ, Butt AA (2021) Effectiveness of the BNT162B2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Eng J Med 385:187–189. https://doi.org/10.1056/NEJMc2104974</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2104974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Choi A, Koch M et al (2021) Preliminary analysis of safety and Immunogenicity of a SARS-coV‑2 variant vaccine booster. MedRxiv preprint. https://doi.org/10.1101/2021.05.05.21256716</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.05.21256716</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A et al (2021) Safety and efficacy of a single dose Ad26.COV2.S vaccine against COVID-19. N Eng J Med 384:2187–2201. https://doi.org/10.1056/NEJMoa2101544</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId></ArticleIdList></Reference><Reference><Citation>Buss LF, Prete CA Jr, Abrahim CMM et al (2021) Three quarters attack rate of SARS-CoV‑2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 371:288–292. https://doi.org/10.1126/science.abe9728</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe9728</ArticleId><ArticleId IdType="pubmed">33293339</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria NR, Claro IM, Candido D et al Genomic characterisation of an emergent SARS-CoV‑2 lineage in manaus. Preliminary findings. Virological.org. https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov2-lineage-in-manaus-preliminary-findings/586 (Erstellt: 20. Jan. 2021). Zugegriffen: 1. Juni 2021</Citation></Reference><Reference><Citation>https://worldometers.info/coronavirus/country/brazil . Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Coutinho RM, Marquitti FMD, Ferreira LS et al Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant. MedRxiv 23.03.2021. https://medrxiv.org/content/10.1101/2021.03.03.21252706v3 . Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Faria NR, Mellan TA, Whittaker C et al (2021) Genomics and epidemiology of the P.1 SARS-CoV‑2 lineage in Manaus, Brazil. Science 372:815–821. https://doi.org/10.1126/science.ahb2644</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.ahb2644</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId><ArticleId IdType="pmcid">8139423</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas ARR, Lemos DRQ, Beckedorff OA, De Goes Cavalcanti LP, Siqueria AM, de Mello SRC, Barros ENC The increase in the risk of severity and fatality rate of Covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P.1 was greater among young adults without preexisting risk conditions. MedRxiv. https://doi.org/10.1101/2021.04.13.21255281 . Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Wang P, Wang M, Yu J et al (2021) Increased resistance of SARS_coV‑2 variant P.1 to antibody neutralization. BioRxiv. https://doi.org/10.1101/2021.03.01.433466</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.01.433466</ArticleId></ArticleIdList></Reference><Reference><Citation>Emergency Use Authorization USA https://fda.gov/media/145802/download (Erstellt: 14. Mai 2021). Zugegriffen: 30. Mai 2021</Citation></Reference><Reference><Citation>Dejnirattisai W, Zhou D, Supasa P et al (2021) Antibody evasion by the P.1 strain of SARS-coV‑2. Cell 184(11):2939–2954.e9. https://doi.org/10.1016/j.cell.2021.03.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.055</ArticleId><ArticleId IdType="pubmed">33852911</ArticleId><ArticleId IdType="pmcid">8008340</ArticleId></ArticleIdList></Reference><Reference><Citation>https://gisaid.org/hcov19-variants/ . Zugegriffen: 1. Juni 2021</Citation></Reference><Reference><Citation>Greany AJ, Loes AN, Crawford KHD et al (2021) Comprehensive mapping of mutations in the SARS-CoV‑2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29:P463–P476.e6. https://doi.org/10.1016/j.chom.2021.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>https://outbreak.info/situation-reports?pango=B.1.617.2&amp;selected=IND&amp;loc=IND . Zugegriffen: 1. Juni 2021</Citation></Reference><Reference><Citation>https://worldometers.info/coronavirus/country/india . Zugegriffen: 1. Juni 2021</Citation></Reference><Reference><Citation>https://www.newindianexpress.com/nation/2021/apr/27/mahakumbh-impact-uttarakhand-active-covid-caseload-jumped-1800-in-25-days-2295337.html . Zugegriffen: 28. Juni 2021</Citation></Reference><Reference><Citation>https://www.gov.uk/government/publications/sage-89-minutes-coronavirus-covid-19-response-13-may-2021/sage-89-minutes-coronavirus-covid-19-response-13-may-2021 . Zugegriffen: 1. Juni 2021</Citation></Reference><Reference><Citation>SARS-CoV‑2 variants of concern and variants under investigation in England. Technical Briefing 10. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_10_England.pdf (Erstellt: 7. Mai 2021). Zugegriffen: 1. Juni 2021</Citation></Reference><Reference><Citation>SARS-CoV‑2 variants of concern and variants under investigation in England. Technical Briefing 17. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/984274/Variants_of_Concern_VOC_Technical_Briefing_17_England.pdf (Erstellt: 25. Juni 2021). Zugegriffen: 28. Juni 2021</Citation></Reference><Reference><Citation>Fisman DN, Tuite AR (2021) Progressive Increase in Virulence of Novel SARS-CoV‑2 Variants in Ontario, Canada. MedRxiv. https://doi.org/10.1101/2021.07.05.21260050</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.05.21260050</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Chiew CJ, Ang LW et al Clinical and virological features of SARS-coV‑2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (beta), and B.1.617.2 (delta). Preprint 07.06.1921. https://europepmc.org/article/ppr/ppr356279 https://doi.org/10.2139/ssrn.3861566 . Zugegriffen: 10. Juli 2021</Citation></Reference><Reference><Citation>Sheikh A, McManin J, Taylor B, Robertson C, Public Health Scotlandand the EAVE II Collaborators (2021) SARS-CoV‑2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397:P2461–2462. https://doi.org/10.1016/S0140-6736(21)01358-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01358-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Hoffmann-Winkler H, Krüger N et al (2021) SARS-CoV‑2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep 36:109415. https://doi.org/10.1016/j.celrep.2021.109415</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109415</ArticleId><ArticleId IdType="pubmed">34270919</ArticleId><ArticleId IdType="pmcid">8238662</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C et al (2021) Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. https://doi.org/10.1056/NEJMoa2108891</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108891</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId><ArticleId IdType="pmcid">8314739</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara VV, Lai L, Sahoo MK et al (2021) Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV‑2 B.1.617.1 variant. BioRxiv. https://doi.org/10.1101/2021.05.09.443299</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.09.443299</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia PY, Ong SWX, Chiew CJ et al (2021) Virological and serological kinetics of SARS-CoV‑2 Delta variant vaccine- 1 breakthrough infections: a multi-center cohort study. MedRxiv. https://www.medrxiv.org/content/10.1101/2021.07.28.21261295v1.full.pdf https://doi.org/10.1101/2021.07.28.21261295 . Zugegriffen: 1. Aug. 2021</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>